{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:43:28Z","timestamp":1776620608032,"version":"3.51.2"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1097\/mph.0b013e3182707592","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:28:35Z","timestamp":1371158915000},"page":"611-616","source":"Crossref","is-referenced-by-count":27,"title":["Peripheral T-cell Lymphoma in Children and Adolescents"],"prefix":"10.1097","volume":"34","author":[{"given":"Rabah","family":"Al Mahmoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abdelhaleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-5-20210227","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ajh.20649","article-title":"Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution.","volume":"81","author":"Lee","year":"2006","journal-title":"Am J Hematol"},{"key":"R3-5-20210227","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2559.1999.00721.x","article-title":"Clinicopathological analysis of 501 non-Hodgkins lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms.","volume":"35","author":"Lee","year":"1999","journal-title":"Histopathology"},{"key":"R4-5-20210227","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"R5-5-20210227","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma.","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"R6-5-20210227","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1995.13.2.359","article-title":"Non-Hodgkins lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stagea report of the Berlin-Frankfurt-Munster Group.","volume":"13","author":"Reiter","year":"1995","journal-title":"J Clin Oncol"},{"key":"R7-5-20210227","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/pbc.22329","article-title":"Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.","volume":"54","author":"Kobayashi","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R8-5-20210227","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/pbc.21293","article-title":"Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.","volume":"50","author":"Windsor","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R9-5-20210227","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pbc.21543","article-title":"Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Childrens Oncology Group study.","volume":"51","author":"Hutchison","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R11-5-20210227","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"R12-5-20210227","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/PAS.0b013e31817f123e","article-title":"Peripheral T-cell lymphoma with follicular T-cell markers.","volume":"32","author":"Rodriguez-Pinilla","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R13-5-20210227","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/annonc\/mdh409","article-title":"Towards understanding the peripheral T-cell lymphomas.","volume":"15","author":"Armitage","year":"2004","journal-title":"Ann Oncol"},{"key":"R14-5-20210227","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrclinonc.2009.169","article-title":"Gamma-delta T-cell lymphomas.","volume":"6","author":"Tripodo","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"R15-5-20210227","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/blood.V88.9.3626.bloodjournal8893626","article-title":"Posttransplant T-cell lymphoproliferative disordersan aggressive, late complication of solid-organ transplantation.","volume":"88","author":"Hanson","year":"1996","journal-title":"Blood"},{"key":"R16-5-20210227","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2004.05212.x","article-title":"T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience.","volume":"127","author":"Draoua","year":"2004","journal-title":"Br J Haematol"},{"key":"R17-5-20210227","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1600-6143.2004.00521.x","article-title":"Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature.","volume":"4","author":"Rajakariar","year":"2004","journal-title":"Am J Transplant"},{"key":"R18-5-20210227","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/pbc.21072","article-title":"Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation.","volume":"50","author":"Yang","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R19-5-20210227","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pbc.21171","article-title":"Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorderlymphoma.","volume":"50","author":"Williams","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R21-5-20210227","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R22-5-20210227","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MPG.0b013e3181957a11","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.","volume":"48","author":"Mackey","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R24-5-20210227","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"key":"R25-5-20210227","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"R26-5-20210227","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"R27-5-20210227","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"R28-5-20210227","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","article-title":"A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (campath-FCD) in peripheral T-cell lymphomas.","volume":"51","author":"Weidmann","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"R29-5-20210227","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"R30-5-20210227","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"R31-5-20210227","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"R32-5-20210227","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: US Food and Drug Administration drug approval summary.","volume":"16","author":"Malik","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"R33-5-20210227","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminhematol.2010.01.014","article-title":"Novel agents in development for peripheral T-cell lymphoma.","volume":"47","author":"OConnor","year":"2010","journal-title":"Semin Hematol"},{"key":"R34-5-20210227","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the Pivotal PROPEL Study.","volume":"29","author":"OConner","year":"2011","journal-title":"J Clin Oncol"},{"key":"R35-5-20210227","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-007-0254-1","article-title":"High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.","volume":"86","author":"Kim","year":"2007","journal-title":"Ann Hematol"},{"key":"R36-5-20210227","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R37-5-20210227","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R38-5-20210227","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"key":"R39-5-20210227","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkins lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"R40-5-20210227","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"key":"R41-5-20210227","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2008.10.011","article-title":"Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.","volume":"71","author":"Rodriguez","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"R42-5-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.10466","article-title":"Hepatosplenic gammadelta T-cell lymphoma in a 10-year-old boy successfully treated with hematopoietic stem cell transplantation.","volume":"75","author":"Gassas","year":"2004","journal-title":"Am J Hematol"},{"key":"R43-5-20210227","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.mph.0000187431.37369.f5","article-title":"Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature.","volume":"27","author":"Domm","year":"2005","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0b013e3182707592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T10:32:54Z","timestamp":1715509974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201211000-00005"}},"subtitle":["A Single-institution Experience"],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3182707592","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}